{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:26:48Z","timestamp":1780514808037,"version":"3.54.1"},"reference-count":7,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Upadacitinib, a selective Janus kinase (JAK) 1 inhibitor, is approved for the treatment of moderate-to-severe inflammatory bowel disease (IBD). Although clinical trials and real-world studies support its efficacy and overall safety profile, rare high-acuity adverse events are emerging with broader use. We describe three complications temporally associated with therapy: invasive hypopharyngeal squamous cell carcinoma (SCC), severe anemia requiring transfusion in the setting of refractory pouchitis with acute pulmonary embolism, and pulmonary blastomycosis. Although causality cannot be established, these cases highlight the need for vigilance for malignancy, hematologic abnormalities, and opportunistic infections, and emphasize careful risk stratification, individualized monitoring, and prompt evaluation of atypical symptoms.<\/jats:p>","DOI":"10.1093\/ecco-jcc\/jjag058","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T11:39:18Z","timestamp":1775907558000},"source":"Crossref","is-referenced-by-count":1,"title":["Beyond the bowel: three rare complications of upadacitinib therapy in inflammatory bowel disease"],"prefix":"10.1093","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1557-6013","authenticated-orcid":false,"given":"Sam","family":"Papasotiriou","sequence":"first","affiliation":[{"name":"University of Illinois Chicago , 1740 W Taylor St , Chicago, Illinois, 60612,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3268-932X","authenticated-orcid":false,"given":"Stephen B","family":"Hanauer","sequence":"additional","affiliation":[{"name":"Northwestern University Feinberg School of Medicine , 259 E Erie St , Chicago, Illinois, 60611,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"2026051319591952500_jjag058-B1","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s12664-024-01720-0","article-title":"Insights into adverse events and safety profile of upadacitinib in the management of inflammatory bowel diseases \u2013 a meta-analysis of randomized controlled trials","volume":"44","author":"Falcon","year":"2025","journal-title":"Indian J Gastroenterol"},{"key":"2026051319591952500_jjag058-B2","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.cgh.2023.03.001","article-title":"Upadacitinib is effective and safe in both ulcerative colitis and Crohn\u2019s disease: prospective real-world experience","volume":"21","author":"Friedberg","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026051319591952500_jjag058-B3","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1016\/j.cgh.2021.12.030","article-title":"Upadacitinib was efficacious and well tolerated over 30 months in patients with Crohn\u2019s disease in the CELEST extension study","volume":"20","author":"D\u2019Haens","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026051319591952500_jjag058-B4","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn\u2019s disease","volume":"388","author":"Sandborn","year":"2023","journal-title":"N Engl J Med"},{"key":"2026051319591952500_jjag058-B5","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000004953","article-title":"Aggressive squamous cell \u00adcarcinoma during treatment with upadacitinib","author":"Hentati","year":"2025","journal-title":"Dermatol Surg"},{"key":"2026051319591952500_jjag058-B6","doi-asserted-by":"publisher","first-page":"e70143","DOI":"10.1002\/prp2.70143","article-title":"Upadacitinib-induced hemolysis in a patient with glucose-6-phosphate dehydrogenase deficiency\u2014a possible adverse drug reaction","volume":"13","author":"Patan\u00e8","year":"2025","journal-title":"Pharmacol. Res. Perspect"},{"key":"2026051319591952500_jjag058-B7","author":"US Food and Drug Administration"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/5\/jjag058\/68281438\/jjag058.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/5\/jjag058\/68281438\/jjag058.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T23:59:21Z","timestamp":1778716761000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjag058\/8677702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":7,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjag058","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,5]]},"article-number":"jjag058"}}